Iterum Therapeutics (NASDAQ:ITRM) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Iterum Therapeutics (NASDAQ:ITRM) from a hold rating to a sell rating in a research report released on Saturday morning.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Iterum Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $9.00.

Iterum Therapeutics Stock Performance

Shares of Iterum Therapeutics stock traded up $0.02 on Friday, hitting $0.60. The company’s stock had a trading volume of 732,849 shares, compared to its average volume of 849,980. The company has a market capitalization of $29.07 million, a price-to-earnings ratio of -0.71 and a beta of 3.09. Iterum Therapeutics has a 1 year low of $0.57 and a 1 year high of $3.02. The firm has a fifty day moving average price of $0.69 and a 200-day moving average price of $0.85.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Iterum Therapeutics stock. Jane Street Group LLC bought a new position in shares of Iterum Therapeutics PLC (NASDAQ:ITRM) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 92,943 shares of the company’s stock, valued at approximately $92,000. Jane Street Group LLC owned approximately 0.21% of Iterum Therapeutics as of its most recent SEC filing. 9.21% of the stock is owned by institutional investors and hedge funds.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.